Meeting
2020 ASCO Virtual Scientific Program
A phase I clinical trial on intratumoral and intracavitary administration of ipilimumab and nivolumab in patients with recurrent glioblastoma.
Authors
Julia Katharina Schwarze
Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium
Julia Katharina Schwarze , Johnny Duerinck , Ines Dufait , Gil Awada , Samuel Klein , Lydia Fischbuch , Laura Seynaeve , Freya Vaeyens , Anne Rogiers , Hendrik Everaert , Anne-Marie Vanbinst , Alex Michotte , Bart Neyns
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT03233152
Citation
J Clin Oncol 38: 2020 (suppl; abstr 2534)
DOI
10.1200/JCO.2020.38.15_suppl.2534
Abstract #
2534
Poster Bd #
25
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).
First Author: Julia Katharina Schwarze
Poster
2018 ASCO Annual Meeting
Phase I study of procaspase activating compound-1 (PAC-1) for treatment of advanced malignancies.
First Author: Oana C. Danciu
Poster
2015 ASCO Annual Meeting
Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143.
First Author: John H. Sampson
Poster
2014 ASCO Annual Meeting
Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).
First Author: John Howard Sampson